Search results
Showing 1096 to 1110 of 1240 results for pain
EarlySense for heart and respiratory monitoring and predicting patient deterioration (MIB49)
NICE has developed a medtech innovation briefing (MIB) on EarlySense for heart and respiratory monitoring and predicting patient deterioration
Baricitinib for treating moderate to severe atopic dermatitis (TA681)
Evidence-based recommendations on baricitinib for treating moderate to severe atopic dermatitis in adults.
Lanadelumab for preventing recurrent attacks of hereditary angioedema (TA606)
Evidence-based recommendations on lanadelumab (Takhzyro) for preventing recurrent attacks of hereditary angioedema in people aged 12 and over.
Discontinued Reference number: GID-TA10310
This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for people by ensuring that they get the most effective tests and treatments, and that they have access to suitable palliative care and follow-up.
Digital therapy for chronic tic disorders and Tourette syndrome: early value assessment (HTG748)
Early value assessment (EVA) guidance on digital therapy for chronic tic disorders and Tourette syndrome.
Evidence-based recommendations on automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcers.
Evidence-based recommendations on Memokath 051 Ureter stent for ureteric obstruction.
Percutaneous intradiscal electrothermal therapy for lower back pain (IPG81)
This guidance has been updated and replaced by NICE interventional procedure guidance 319.
Percutaneous intradiscal radiofrequency thermocoagulation for lower back pain (IPG83)
Interventional procedures, IPG83 - Issued: August 2004 --> This guidance has been updated and replaced by NICE interventional procedure guidance 545.
Percutaneous intradiscal electrothermal therapy for low back pain (IPG319)
Interventional procedures, IPG319 - Issued: November 2009 --> This guidance has been updated and replaced by NICE interventional procedure guidance 544.
Zanubrutinib for treating Waldenstrom's macroglobulinaemia (TA833)
Evidence-based recommendations on zanubrutinib (Brukinsa) for treating Waldenstrom’s macroglobulinaemia in adults.
Evidence-based recommendations on apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer in adults.
Evidence-based recommendations on dinutuximab beta (Qarziba) for high-risk neuroblastoma in people aged 12 months and over.
Mannitol dry powder for inhalation for treating cystic fibrosis (TA266)
Evidence-based recommendations on mannitol dry powder for inhalation (Bronchitol) for treating cystic fibrosis in adults